Perspectives From a Leading Alzheimer’s Disease Researcher

Dr. David Henley, MD, Executive Medical Director, Alzheimer’s Disease Global Medical Affairs, Neurology Business Group at Eisai Inc. shares his perspective on recent advances in Alzheimer’s Disease research and therapeutic approaches including the role of the amyloid-beta pathway. 

David Henley, MD serves as Eisai’s Neurology Business Group (NBG) Executive Medical Director leading Eisai’s Alzheimer’s disease brand development, HCP education and external KOL interactions. He is also a cross-functional team leader within the Global Medical Affairs team and the Neurology Business Group organization working on Eisai’s Alzheimer’s Disease pipeline while prioritizing strategic scientific development and medical advocacy.

Dr. Henley has over 17 years of experience in late-stage drug development and global /US medical affairs involving Alzheimer’s disease compounds. Prior to joining Eisai, Dr. Henley was a Senior Director of AD clinical development for the Neurodegeneration Team at Janssen Research & Development, serving as clinical leader for Janssen’s BACE inhibitor and anti-tau monoclonal antibody programs as well as a senior medical director of global and US AD medical affairs at Eli Lilly.

Dr. Henley is also a volunteer Clinical Assistant Professor of Psychiatry at Indiana University (IU) School of Medicine. He completed his medical degree from IU School of Medicine and carried out his residency at IU Department of Psychiatry. He started his career providing general adult/geriatric psychiatric inpatient, outpatient and nursing home care.